BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakao K, Miyaaki H, Ichikawa T. Antitumor function of microRNA-122 against hepatocellular carcinoma. J Gastroenterol. 2014;49:589-593. [PMID: 24531873 DOI: 10.1007/s00535-014-0932-4] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 10.4] [Reference Citation Analysis]
Number Citing Articles
1 Cao F, Yin LX. miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway. Exp Mol Pathol 2019;106:34-43. [PMID: 30539797 DOI: 10.1016/j.yexmp.2018.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
2 Li C, Wu X, Zhang H, Yang G, Hao M, Sheng S, Sun Y, Long J, Hu C, Sun X, Li L, Zheng J. A Huaier polysaccharide reduced metastasis of human hepatocellular carcinoma SMMC-7721 cells via modulating AUF-1 signaling pathway. Tumour Biol 2015;36:6285-93. [PMID: 25787750 DOI: 10.1007/s13277-015-3314-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
3 Guo HL, Chen LD, Li W, Liang JY, Zhang JC, Li X, Xie XY, Lu MD, Kuang M, Wang W. Ultrasomics for Early Evaluation of the Tumor Response to MicroRNA-122 in a Nude Mouse Hepatocellular Carcinoma Model. J Ultrasound Med 2020;39:61-71. [PMID: 31225651 DOI: 10.1002/jum.15071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Yarushkin AA, Kazantseva YA, Kobelev VS, Pustylnyak YA, Pustylnyak VO. Peroxisome proliferator-activated receptor γ activation inhibits liver growth through miR-122-mediated downregulation of cMyc. Eur J Pharmacol 2017;797:39-44. [PMID: 28095325 DOI: 10.1016/j.ejphar.2017.01.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jilek JL, Zhang QY, Tu MJ, Ho PY, Duan Z, Qiu JX, Yu AM. Bioengineered Let-7c Inhibits Orthotopic Hepatocellular Carcinoma and Improves Overall Survival with Minimal Immunogenicity. Mol Ther Nucleic Acids 2019;14:498-508. [PMID: 30753993 DOI: 10.1016/j.omtn.2019.01.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
6 Zuo X, Chen Z, Cai J, Gao W, Zhang Y, Han G, Pu L, Wu Z, You W, Qin J, Dai X, Shen H, Wu J, Wang X. 5-Hydroxytryptamine Receptor 1D Aggravates Hepatocellular Carcinoma Progression Through FoxO6 in AKT-Dependent and Independent Manners. Hepatology 2019;69:2031-47. [PMID: 30561038 DOI: 10.1002/hep.30430] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
7 Yang X, Sun L, Wang L, Yao B, Mo H, Yang W. LncRNA SNHG7 accelerates the proliferation, migration and invasion of hepatocellular carcinoma cells via regulating miR-122-5p and RPL4. Biomedicine & Pharmacotherapy 2019;118:109386. [DOI: 10.1016/j.biopha.2019.109386] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
8 Rivero-Hinojosa S, Lau LS, Stampar M, Staal J, Zhang H, Gordish-Dressman H, Northcott PA, Pfister SM, Taylor MD, Brown KJ, Rood BR. Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. Acta Neuropathol Commun 2018;6:48. [PMID: 29880060 DOI: 10.1186/s40478-018-0548-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
9 Li C, Deng M, Hu J, Li X, Chen L, Ju Y, Hao J, Meng S. Chronic inflammation contributes to the development of hepatocellular carcinoma by decreasing miR-122 levels. Oncotarget. 2016;7:17021-17034. [PMID: 26933995 DOI: 10.18632/oncotarget.7740] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
10 Wang M, Yu F, Li P. Circular RNAs: Characteristics, Function and Clinical Significance in Hepatocellular Carcinoma. Cancers (Basel) 2018;10:E258. [PMID: 30072625 DOI: 10.3390/cancers10080258] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 18.0] [Reference Citation Analysis]
11 Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122--a key factor and therapeutic target in liver disease. J Hepatol. 2015;62:448-457. [PMID: 25308172 DOI: 10.1016/j.jhep.2014.10.004] [Cited by in Crossref: 315] [Cited by in F6Publishing: 291] [Article Influence: 45.0] [Reference Citation Analysis]
12 Wu C, Zhang J, Cao X, Yang Q, Xia D. Effect of Mir-122 on Human Cholangiocarcinoma Proliferation, Invasion, and Apoptosis Through P53 Expression. Med Sci Monit 2016;22:2685-90. [PMID: 27472451 DOI: 10.12659/msm.896404] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 3.2] [Reference Citation Analysis]
13 Zhang HT, Sun J, Yan Y, Cui SH, Wang H, Wang CH, Qiu C, Chen X, Ding JS, Qian HG, Wang JC, Zhang Q. Encapsulated microRNA by gemcitabine prodrug for cancer treatment. J Control Release 2019;316:317-30. [PMID: 31733293 DOI: 10.1016/j.jconrel.2019.11.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 El Kassas M, Tawheed A, Eltabbakh M, Kaseb A. Hepatitis C Antiviral Therapy In Patients With Successfully Treated Hepatocellular Carcinoma: Dancing With Wolves. J Hepatocell Carcinoma 2019;6:183-91. [PMID: 31819865 DOI: 10.2147/JHC.S206668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Hashemi F, Samarghandian S, Najafi M. MicroRNAs in cancer therapy: Their involvement in oxaliplatin sensitivity/resistance of cancer cells with a focus on colorectal cancer. Life Sci 2020;256:117973. [PMID: 32569779 DOI: 10.1016/j.lfs.2020.117973] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
16 Kunden RD, Khan JQ, Ghezelbash S, Wilson JA. The Role of the Liver-Specific microRNA, miRNA-122 in the HCV Replication Cycle. Int J Mol Sci. 2020;21. [PMID: 32784807 DOI: 10.3390/ijms21165677] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
17 Yang AY, Kim H, Li W, Kong AN. Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers. Curr Top Med Chem 2016;16:697-713. [PMID: 26306989 DOI: 10.2174/1568026615666150826114359] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
18 Shi KQ, Lin Z, Chen XJ, Song M, Wang YQ, Cai YJ, Yang NB, Zheng MH, Dong JZ, Zhang L, Chen YP. Hepatocellular carcinoma associated microRNA expression signature: integrated bioinformatics analysis, experimental validation and clinical significance. Oncotarget 2015;6:25093-108. [PMID: 26231037 DOI: 10.18632/oncotarget.4437] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 12.4] [Reference Citation Analysis]
19 de Paula Simino LA, de Fante T, Figueiredo Fontana M, Oliveira Borges F, Torsoni MA, Milanski M, Velloso LA, Souza Torsoni A. Lipid overload during gestation and lactation can independently alter lipid homeostasis in offspring and promote metabolic impairment after new challenge to high-fat diet. Nutr Metab (Lond) 2017;14:16. [PMID: 28239403 DOI: 10.1186/s12986-017-0168-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
20 Li M, Tang Y, Wu L, Mo F, Wang X, Li H, Qi R, Zhang H, Srivastava A, Ling C. The hepatocyte-specific HNF4α/miR-122 pathway contributes to iron overload-mediated hepatic inflammation. Blood 2017;130:1041-51. [PMID: 28655781 DOI: 10.1182/blood-2016-12-755967] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
21 Taniguchi K, Uchiyama K, Akao Y. PTBP1-targeting microRNAs regulate cancer-specific energy metabolism through the modulation of PKM1/M2 splicing. Cancer Sci 2021;112:41-50. [PMID: 33070451 DOI: 10.1111/cas.14694] [Reference Citation Analysis]
22 Nabi AA, Atta SA, El-Ahwany E, Elzayat E, Saleh H. Taurine Upregulates miRNA-122-5p Expression and Suppresses the Metabolizing Enzymes of Glycolytic Pathway in Hepatocellular Carcinoma. Mol Biol Rep 2021;48:5549-59. [PMID: 34313924 DOI: 10.1007/s11033-021-06571-y] [Reference Citation Analysis]
23 Suehiro T, Miyaaki H, Kanda Y, Shibata H, Honda T, Ozawa E, Miuma S, Taura N, Nakao K. Serum exosomal microRNA-122 and microRNA-21 as predictive biomarkers in transarterial chemoembolization-treated hepatocellular carcinoma patients. Oncol Lett. 2018;16:3267-3273. [PMID: 30127924 DOI: 10.3892/ol.2018.8991] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
24 Xiong Q, Bai Y, Shi R, Wang J, Xu W, Zhang M, Song T. Preferentially released miR-122 from cyclodextrin-based star copolymer nanoparticle enhances hepatoma chemotherapy by apoptosis induction and cytotoxics efflux inhibition. Bioact Mater 2021;6:3744-55. [PMID: 33898875 DOI: 10.1016/j.bioactmat.2021.03.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Théret N, Bouezzedine F, Azar F, Diab-Assaf M, Legagneux V. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. Cancers (Basel) 2021;13:1563. [PMID: 33805340 DOI: 10.3390/cancers13071563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Huan H, Wen X, Chen X, Wu L, Liu W, Habib NA, Bie P, Xia F. C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling Mediated EMT. PLoS One 2016;11:e0153117. [PMID: 27050434 DOI: 10.1371/journal.pone.0153117] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
27 Hamilton G, Teufelsbauer M. Adipose-derived stromal/stem cells and extracellular vesicles for cancer therapy. Expert Opin Biol Ther 2021;:1-12. [PMID: 34236014 DOI: 10.1080/14712598.2021.1954156] [Reference Citation Analysis]
28 Szabo G, Csak T. Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci. 2016;61:1314-1324. [PMID: 26769057 DOI: 10.1007/s10620-015-4002-4] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
29 Meng L, Chen Z, Jiang Z, Huang T, Hu J, Luo P, Zhang H, Huang M, Huang L, Chen Y, Lu M, Xu AM, Ying S. MiR-122-5p suppresses the proliferation, migration, and invasion of gastric cancer cells by targeting LYN. Acta Biochim Biophys Sin (Shanghai) 2020;52:49-57. [PMID: 31828293 DOI: 10.1093/abbs/gmz141] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
30 Alamoudi AA, Alnoury A, Gad H. miRNA in tumour metabolism and why could it be the preferred pathway for energy reprograming. Briefings in Functional Genomics 2018;17:157-69. [DOI: 10.1093/bfgp/elx023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
31 Jin K, Li T, Sánchez-Duffhues G, Zhou F, Zhang L. Involvement of inflammation and its related microRNAs in hepatocellular carcinoma. Oncotarget 2017;8:22145-65. [PMID: 27888618 DOI: 10.18632/oncotarget.13530] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
32 Morishita A, Masaki T. MicroRNAs as possible biomarkers for hepatocellular carcinoma: MiRNAs as biomarkers for HCC. Hepatol Res 2018;48:499-501. [DOI: 10.1111/hepr.13078] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
33 Zhang P, Shen M, Fernandez-Patron C, Kassiri Z. ADAMs family and relatives in cardiovascular physiology and pathology. J Mol Cell Cardiol 2016;93:186-99. [PMID: 26522853 DOI: 10.1016/j.yjmcc.2015.10.031] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
34 Elhefnawi M, Salah Z, Soliman B. The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma. CGT 2019;19:290-304. [DOI: 10.2174/1566523219666191023101433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Verano-Braga T, Gorshkov V, Munthe S, Sørensen MD, Kristensen BW, Kjeldsen F. SuperQuant-assisted comparative proteome analysis of glioblastoma subpopulations allows for identification of potential novel therapeutic targets and cell markers. Oncotarget 2018;9:9400-14. [PMID: 29507698 DOI: 10.18632/oncotarget.24321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
36 Yang G, Zhang M, Zhao Y, Pan Y, Kan M, Li J, He K, Zhang X. HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway. PLoS One 2020;15:e0230450. [PMID: 32210451 DOI: 10.1371/journal.pone.0230450] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
37 Koduru SV, Tiwari AK, Leberfinger A, Hazard SW, Kawasawa YI, Mahajan M, Ravnic DJ. A Comprehensive NGS Data Analysis of Differentially Regulated miRNAs, piRNAs, lncRNAs and sn/snoRNAs in Triple Negative Breast Cancer. J Cancer. 2017;8:578-596. [PMID: 28367238 DOI: 10.7150/jca.17633] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
38 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2016;46:391-406. [PMID: 26490438 DOI: 10.1111/hepr.12606] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
39 Huang JT, Liu SM, Ma H, Yang Y, Zhang X, Sun H, Zhang X, Xu J, Wang J. Systematic Review and Meta-Analysis: Circulating miRNAs for Diagnosis of Hepatocellular Carcinoma. J Cell Physiol. 2016;231:328-335. [PMID: 26291451 DOI: 10.1002/jcp.25135] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
40 Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, Thum T. MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma. PLoS One 2015;10:e0139305. [PMID: 26431155 DOI: 10.1371/journal.pone.0139305] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
41 Cheng D, Deng J, Zhang B, He X, Meng Z, Li G, Ye H, Zheng S, Wei L, Deng X, Chen R, Zhou J. LncRNA HOTAIR epigenetically suppresses miR-122 expression in hepatocellular carcinoma via DNA methylation. EBioMedicine. 2018;36:159-170. [PMID: 30195653 DOI: 10.1016/j.ebiom.2018.08.055] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 18.3] [Reference Citation Analysis]
42 Braoudaki M, Lambrou GI, Giannikou K, Milionis V, Stefanaki K, Birks DK, Prodromou N, Kolialexi A, Kattamis A, Spiliopoulou CA, Tzortzatou-Stathopoulou F, Kanavakis E. Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms. J Hematol Oncol 2014;7:96. [PMID: 25551588 DOI: 10.1186/s13045-014-0096-y] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
43 Yan JJ, Chang Y, Zhang YN, Lin JS, He XX, Huang HJ. miR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma. Oncol Lett. 2017;13:3118-3126. [PMID: 28529562 DOI: 10.3892/ol.2017.5826] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
44 Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang SY, He DX, Tang SS, Wei H, Yu CY. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma. ACS Appl Mater Interfaces 2019;11:10578-88. [PMID: 30802029 DOI: 10.1021/acsami.9b00634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
45 Shi Y, Huang A. Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs. Tumor Biol 2015;36:8455-63. [DOI: 10.1007/s13277-015-3565-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
46 Azer SA. MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options? J Clin Med 2018;7:E64. [PMID: 29584707 DOI: 10.3390/jcm7040064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
47 Deng M, Qin Y, Chen X, Wang Q, Wang J. MiR-206 inhibits proliferation, migration, and invasion of gastric cancer cells by targeting the MUC1 gene. Onco Targets Ther 2019;12:849-59. [PMID: 30774372 DOI: 10.2147/OTT.S180021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
48 Huang X, Gong S, Ma Y, Cai X, Zhou L, Luo Y, Li M, Liu W, Zhang S, Zhang X, Ren Q, Zhu Y, Zhou X, Zhang R, Chen L, Gao X, Zhang F, Wang Y, Han X, Ji L. Lower Circulating miR-122 Level in Patients with HNF1A Variant-Induced Diabetes Compared with Type 2 Diabetes. J Diabetes Res 2018;2018:7842064. [PMID: 30155490 DOI: 10.1155/2018/7842064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
49 Butt AS, Sharif F, Abid S. Impact of direct acting antivirals on occurrence and recurrence of hepatocellular carcinoma: Biologically plausible or an epiphenomenon? World J Hepatol 2018;10:267-76. [PMID: 29527262 DOI: 10.4254/wjh.v10.i2.267] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
50 Shi L, Zheng X, Fan Y, Yang X, Li A, Qian J. The contribution of miR-122 to the innate immunity by regulating toll-like receptor 4 in hepatoma cells. BMC Gastroenterol 2019;19:130. [PMID: 31340754 DOI: 10.1186/s12876-019-1048-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
51 Li W, Guo Y, Zhang C, Wu R, Yang AY, Gaspar J, Kong AN. Dietary Phytochemicals and Cancer Chemoprevention: A Perspective on Oxidative Stress, Inflammation, and Epigenetics. Chem Res Toxicol. 2016;29:2071-2095. [PMID: 27989132 DOI: 10.1021/acs.chemrestox.6b00413] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 11.8] [Reference Citation Analysis]
52 Liu G, Wang H, Fu JD, Liu JY, Yan AG, Guan YY. A five-miRNA expression signature predicts survival in hepatocellular carcinoma. APMIS 2017;125:614-22. [PMID: 28430373 DOI: 10.1111/apm.12697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
53 Pascut D, Hoang M, Nguyen NNQ, Pratama MY, Tiribelli C. HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development. Cancers (Basel) 2021;13:2485. [PMID: 34069740 DOI: 10.3390/cancers13102485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Tao X, Yang X, Wu K, Yang L, Huang Y, Jin Q, Chen S. miR-629-5p promotes growth and metastasis of hepatocellular carcinoma by activating β-catenin. Exp Cell Res 2019;380:124-30. [PMID: 30954576 DOI: 10.1016/j.yexcr.2019.03.042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
55 Xu G, Han J, Xu T. Comparative analysis of the small RNA transcriptomes of miiuy croaker revealed microRNA-mediated regulation of TLR signaling pathway response to Vibrio anguillarum infection. Fish Shellfish Immunol 2016;52:248-57. [PMID: 26980609 DOI: 10.1016/j.fsi.2016.03.011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
56 De Matteis S, Ragusa A, Marisi G, De Domenico S, Casadei Gardini A, Bonafè M, Giudetti AM. Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. Oxid Med Cell Longev 2018;2018:7512159. [PMID: 30524660 DOI: 10.1155/2018/7512159] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 16.3] [Reference Citation Analysis]
57 Ambade A, Satishchandran A, Szabo G. Alcoholic hepatitis accelerates early hepatobiliary cancer by increasing stemness and miR-122-mediated HIF-1α activation. Sci Rep 2016;6:21340. [PMID: 26888602 DOI: 10.1038/srep21340] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
58 Kazantseva YA, Yarushkin AA, Mostovich LA, Pustylnyak YA, Pustylnyak VO. Xenosensor CAR mediates down-regulation of miR-122 and up-regulation of miR-122 targets in the liver. Toxicol Appl Pharmacol 2015;288:26-32. [PMID: 26171734 DOI: 10.1016/j.taap.2015.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
59 Van Hees S, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2016;22:8271-8282. [PMID: 27729734 DOI: 10.3748/wjg.v22.i37.8271] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
60 Lu W, Zhang Y, Zhou L, Wang X, Mu J, Jiang L, Hu Y, Dong P, Liu Y. miR-122 inhibits cancer cell malignancy by targeting PKM2 in gallbladder carcinoma. Tumour Biol. 2015;. [PMID: 26546436 DOI: 10.1007/s13277-015-4308-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
61 Li B, Li A, You Z, Xu J, Zhu S. Epigenetic silencing of CDKN1A and CDKN2B by SNHG1 promotes the cell cycle, migration and epithelial-mesenchymal transition progression of hepatocellular carcinoma. Cell Death Dis 2020;11:823. [PMID: 33009370 DOI: 10.1038/s41419-020-03031-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Wu X, Yang Y, Huang Y, Chen Y, Wang T, Wu S, Tong L, Wang Y, Lin L, Hao M, Zhong ZH, Zhang F, Zhao W. RNA-binding protein AUF1 suppresses miR-122 biogenesis by down-regulating Dicer1 in hepatocellular carcinoma. Oncotarget 2018;9:14815-27. [PMID: 29599909 DOI: 10.18632/oncotarget.24079] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
63 Kohno T, Morishita A, Iwama H, Fujita K, Tani J, Takuma K, Nakahara M, Oura K, Tadokoro T, Nomura T, Yoneyama H, Kato K, Okano K, Suzuki Y, Nishiyama A, Himoto T, Masaki T. Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma. Oncol Lett 2020;20:1727-33. [PMID: 32724415 DOI: 10.3892/ol.2020.11696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
64 Liu N, Jiang F, He TL, Zhang JK, Zhao J, Wang C, Jiang GX, Cao LP, Kang PC, Zhong XY, Lin TY, Cui YF. The Roles of MicroRNA-122 Overexpression in Inhibiting Proliferation and Invasion and Stimulating Apoptosis of Human Cholangiocarcinoma Cells. Sci Rep 2015;5:16566. [PMID: 26686459 DOI: 10.1038/srep16566] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
65 Kamimura K, Yokoo T, Abe H, Terai S. Gene Therapy for Liver Cancers: Current Status from Basic to Clinics. Cancers (Basel) 2019;11:E1865. [PMID: 31769427 DOI: 10.3390/cancers11121865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
66 Zhang H, Zhang Z, Gao L, Qiao Z, Yu M, Yu B, Yang T. miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9. Onco Targets Ther 2019;12:2149-57. [PMID: 30962696 DOI: 10.2147/OTT.S197326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
67 Xue F, Lin X, Cai Z, Liu X, Ma Y, Wu M. Doxifluridine-based pharmacosomes delivering miR-122 as tumor microenvironments-activated nanoplatforms for synergistic treatment of hepatocellular carcinoma. Colloids Surf B Biointerfaces 2021;197:111367. [PMID: 33007506 DOI: 10.1016/j.colsurfb.2020.111367] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Schueller F, Roy S, Vucur M, Trautwein C, Luedde T, Roderburg C. The Role of miRNAs in the Pathophysiology of Liver Diseases and Toxicity. Int J Mol Sci. 2018;19:pii: E261. [PMID: 29337905 DOI: 10.3390/ijms19010261] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 17.3] [Reference Citation Analysis]
69 El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. J Adv Res 2019;17:43-8. [PMID: 31193326 DOI: 10.1016/j.jare.2019.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
70 McGill MR, Jaeschke H. Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients. Expert Opin Drug Metab Toxicol 2014;10:1005-17. [PMID: 24836926 DOI: 10.1517/17425255.2014.920823] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 10.4] [Reference Citation Analysis]
71 Cao N, Li M, Han J, Wang Y, Wang X. rs61991156 in miR-379 is associated with low capability of glycolysis of gastric cancer by enhanced regulation of PKM2. Cancer Cell Int 2018;18:92. [PMID: 29997453 DOI: 10.1186/s12935-018-0593-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]